Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/21650Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rani, Preeti | - |
| dc.contributor.author | Srivastava, V K | - |
| dc.contributor.author | Kurnar, Ashok | - |
| dc.date.accessioned | 2013-10-07T10:14:37Z | - |
| dc.date.available | 2013-10-07T10:14:37Z | - |
| dc.date.issued | 2003-07 | - |
| dc.identifier.issn | 0975-0983(Online); 0376-4699(Print) | - |
| dc.identifier.uri | http://hdl.handle.net/123456789/21650 | - |
| dc.description | 1729-1733 | en_US |
| dc.description.abstract | A number of 5-substituted-N-[4'-(substitutedphenyl)aminomethyl-5' (substitutedphenyl)isoxazolin-2'-yl]anthranilic acids have been synthesized by the Mannich reaction of 5-substituted-N-[5'-(substitutedphenyl)isoxazolin-2'-y l]anthranilic acids, which in turn is synthesized by the reaction of 5-substituted-N-chalconylanthranilic acids. In this series, compounds 9,11, 15 and 18 show significant protection against carrageenan induced rat's paw oedema with lower ulcerogenic liability than phenylbutazone. The most active compound of this series is N-[5'-(m-methoxy, p-hydroxyphenyl)isoxazolin-2'yl] anthranilic acid which has shown higher antiinflammatory activity and lower ulcerogenic property than phenylbutazone. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | NISCAIR-CSIR, India | en_US |
| dc.rights |  CC Attribution-Noncommercial-No Derivative Works 2.5 India | en_US |
| dc.source | IJC-B Vol.42B(07) [July 2003] | en_US |
| dc.title | Isoxazolinyl derivatives of anthranilic acid as antiinflammatory agents | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | IJC-B Vol.42B(07) [July 2003] | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJCB 42B(7) 1729-1733.pdf | 925.14 kB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.